Atrial Tachycardia Reduction With Intravenous Use of Magnesium (ATRIUM) Study: Comparing Magnesium 2g Versus 4g Versus Placebo in the Incidence of Treating AFF RVR
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 3
SUMMARY
The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of AFF RVR.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:
• Age \> 18 years or older
• Able to provide informed consent
• Primary diagnosis AFF RVR greater than or equal to 120 bpm
• Diltiazem as rate control agent
• English speaking
Locations
United States
Illinois
Advocate Christ Medical Center Emergency Department (ACMC ED)
RECRUITING
Oak Lawn
Contact Information
Primary
Marc McDowell, PharmD
marc.mcdowell@aah.org
(708) 684-1078
Time Frame
Start Date: 2024-10-07
Estimated Completion Date: 2026-12
Participants
Target number of participants: 153
Treatments
Experimental: Experimental Arm One, Magnesium Sulfate 2g
Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl)
Experimental: Experimental Arm Two, Magnesium Sulfate 4g
Magnesium Sulfate 4g/50ml 0.9% NaCl
Placebo_comparator: Control Arm, normal saline
50ml 0.9% NaCl
Related Therapeutic Areas
Sponsors
Leads: Wake Forest University Health Sciences